JAK3 Gene

Migration, Crosslink

📖

JAK3 Gene

active

wiki page Created: 2026-04-02T07:19:18 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-jak3

📖 Wiki Page

gene1443 wordssynced 2026-04-02

JAK3 — Janus Kinase 3

<div class="infobox infobox-gene">
<div class="infobox-header">JAK3 — Janus Kinase 3</div>
<div class="infobox-row"><strong>Gene Symbol:</strong> JAK3</div>
<div class="infobox-row"><strong>Full Name:</strong> Janus Kinase 3</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 19p13.11</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 3718</div>
<div class="infobox-row"><strong>OMIM:</strong> 600043</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000105639</div>
<div class="infobox-row"><strong>UniProt ID:</strong> P52333</div>
<div class="infobox-row"><strong>Protein Length:</strong> 1124 amino acids</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Severe Combined Immunodeficiency (SCID), Autoimmune Diseases, Neuroinflammation, Alzheimer's Disease, Parkinson's Disease</div>
</div>

Overview

...

JAK3 — Janus Kinase 3

<div class="infobox infobox-gene">
<div class="infobox-header">JAK3 — Janus Kinase 3</div>
<div class="infobox-row"><strong>Gene Symbol:</strong> JAK3</div>
<div class="infobox-row"><strong>Full Name:</strong> Janus Kinase 3</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 19p13.11</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 3718</div>
<div class="infobox-row"><strong>OMIM:</strong> 600043</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000105639</div>
<div class="infobox-row"><strong>UniProt ID:</strong> P52333</div>
<div class="infobox-row"><strong>Protein Length:</strong> 1124 amino acids</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Severe Combined Immunodeficiency (SCID), Autoimmune Diseases, Neuroinflammation, Alzheimer's Disease, Parkinson's Disease</div>
</div>

Overview

Mermaid diagram (expand to render)

JAK3 (Janus Kinase 3) encodes a non-receptor tyrosine kinase that plays essential roles in cytokine receptor signaling, particularly in lymphoid cells. Unlike other JAK family members, JAK3 is expressed predominantly in lymphoid tissues and is required for signaling through the common gamma chain (gammac) family of cytokine receptors. This includes receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, which are critical for T cell development, B cell function, and natural killer cell activity["@oshea2015"].

In the central nervous system, JAK3 is expressed in [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/cell-types/astrocytes), where it mediates cytokine-driven inflammatory responses. This has made JAK3 a focus of interest for understanding neuroinflammation in neurodegenerative diseases like [Alzheimer's Disease](/diseases/alzheimers-disease) and [Parkinson's Disease](/diseases/parkinsons-disease). The JAK-STAT signaling pathway becomes dysregulated in these conditions, contributing to chronic neuroinflammation and neuronal dysfunction. Pharmacological inhibition of JAK3 represents a therapeutic strategy being explored for both autoimmune conditions and neuroinflammatory diseases["@chang2019"].

Discovery and Nomenclature

JAK3 was identified in the 1990s as the third member of the Janus kinase family, which also includes JAK1, JAK2, and TYK2. The name "Janus" derives from the Roman god of beginnings and endings, reflecting the kinase's unique structure with two kinase domains—a functional kinase domain and a pseudokinase domain. JAK3 is unique among JAK family members in its restricted expression pattern and its essential role in γc cytokine receptor signaling.

Protein Structure and Function

Structural Features

JAK3 possesses the characteristic JAK family architecture[@lin2017]:

| Domain | Position | Function |
|--------|----------|----------|
| FERM domain | 1-450 | Receptor binding and localization |
| SH2-like domain | 451-520 | Protein-protein interactions |
| Pseudokinase (JH2) | 521-850 | Regulatory domain, autoinhibition |
| Kinase domain (JH1) | 851-1124 | Catalytic activity |

The pseudokinase domain (JH2) serves a critical regulatory function, maintaining the kinase domain in an inactive conformation until appropriate stimulation occurs. Mutations in this domain can cause constitutive activation or loss of function.

Catalytic Mechanism

JAK3 catalyzes tyrosine phosphorylation of STAT proteins:

Cytokine binding → receptor dimerization

JAK3 activation through trans-phosphorylation

STAT protein recruitment and phosphorylation

STAT dimerization and nuclear translocation

Gene transcription regulation

Cellular Functions

Immune Cell Signaling

JAK3 is essential for signaling through γc cytokine receptors[@park2018]:

IL-2 signaling:

T cell proliferation and survival
Regulatory T cell function
Memory T cell maintenance

IL-4 signaling:

B cell class switching
Th2 cell differentiation

IL-7 signaling:

T cell development in thymus
T cell receptor diversity

IL-15 signaling:

NK cell development
Memory CD8+ T cell survival

IL-21 signaling:

B cell differentiation
Tfh cell function

Neuroinflammation

In the CNS, JAK3 mediates inflammatory responses[@johnston2021][@chen2020]:

Microglial activation:

Pro-inflammatory cytokine production
Phagocytic activity modulation
Synaptic pruning regulation

Astrocyte reactivity:

GFAP expression upregulation
Inflammatory mediator release
Blood-brain barrier modulation

Neuronal effects:

Synaptic plasticity modulation
Excitotoxicity regulation
Survival pathway control

Expression Pattern

Immune System

JAK3 is highly expressed in lymphoid tissues:

| Cell Type | Expression Level |
|-----------|-----------------|
| T cells | Very high |
| NK cells | High |
| B cells | Moderate |
| Mast cells | Moderate |
| Myeloid cells | Low |

Brain Expression

In the central nervous system[@morrissey2018]:

Microglia: Constitutive expression, upregulated in disease
Astrocytes: Moderate expression, increases with activation
Neurons: Low expression, primarily in specific regions
Oligodendrocytes: Limited expression

Regional distribution includes:

[Cerebral Cortex](/brain-regions/cerebral-cortex)
[Hippocampus](/brain-regions/hippocampus)
Basal ganglia
[Cerebellum](/brain-regions/cerebellum)

Role in Neurodegenerative Disease

Alzheimer's Disease

JAK3-mediated neuroinflammation contributes to AD pathology[@yoshida2018][@campbell2019]:

Mechanisms:

Chronic cytokine release drives tau pathology
Microglial activation promotes amyloid clearance defects
Synaptic elimination through excessive pruning
Neuronal dysfunction via STAT3 activation

Therapeutic implications:

JAK3 inhibitors may reduce neuroinflammation
Potential for disease modification
Need for CNS-penetrant compounds

Parkinson's Disease

In PD models, JAK3 signaling contributes to dopaminergic neuron loss[@iwamaru2019]:

Pathogenic mechanisms:

α-synuclein-induced microglial activation
Inflammatory cytokine toxicity
Mitochondrial dysfunction mediation
Neuroinflammation amplification

Potential interventions:

JAK3 blockade in early disease stages
Targeting specific downstream pathways
Combination with other neuroprotective strategies

Other Neurodegenerative Conditions

JAK3 involvement extends to:

Multiple sclerosis
Amyotrophic lateral sclerosis
Huntington's disease
Frontotemporal dementia

Disease Associations

Primary Immunodeficiency

JAK3 deficiency causes severe combined immunodeficiency (SCID)[@kumari2017]:

Clinical features:

Absent T and NK cells
B cell dysfunction
Severe infections
Early-onset

Treatment:

Bone marrow transplantation
Gene therapy (experimental)

Autoimmune Diseases

Dysregulated JAK3 signaling contributes to[@smith2021]:

Rheumatoid arthritis
Inflammatory bowel disease
Psoriasis
Lupus

Cancer

JAK3 is implicated in:

Adult T-cell leukemia/lymphoma
NK/T cell lymphomas
Certain solid tumors

Therapeutic Approaches

JAK Inhibitors

Several JAK inhibitors are approved or in development[@tanaka2020]:

| Drug | Primary Target | Approved For |
|------|----------------|--------------|
| Tofacitinib | JAK1/2/3 | RA, PsA, UC |
| Baricitinib | JAK1/2 | RA, COVID-19 |
| Upadacitinib | JAK1 | RA, PsA |
| Ruxolitinib | JAK1/2 | Myelofibrosis |

Neuroinflammation-Targeting Strategies

For neurodegenerative diseases:

Brain-penetrant JAK inhibitors: Under development
Combination approaches: With other anti-inflammatory agents
Disease-modifying potential: Beyond symptom relief

Clinical Considerations

Risks:

Immunosuppression
Increased infection risk
Potential neurodegeneration paradox
Long-term safety concerns

Benefits in neuroinflammation:

Reduced cytokine-mediated damage
Modulation of microglial phenotype
Potential for disease modification

Molecular Interactions

Receptor Interactions

JAK3 associates with γc cytokine receptor subunits:

IL2RB (common beta chain)
IL2RG (common gamma chain)
IL4R
IL7R
IL9R
IL15R
IL21R

STAT Partners

STAT3: Major signaling partner
STAT5A/B: Important for T cell function
STAT6: IL-4/IL-13 specific

Regulatory Proteins

SOCS proteins: Negative feedback inhibitors
PIAS proteins: STAT inhibitors
Protein tyrosine phosphatases: Signal termination

Signaling Pathways

JAK3 activates multiple downstream pathways:

| Pathway | Outcome |
|---------|---------|
| STAT3 | Gene transcription, survival |
| STAT5 | Immune cell function |
| PI3K/AKT | Cell survival |
| MAPK/ERK | Proliferation |
| NF-κB | Inflammation |

Genetics

Mutation Spectrum

Over 50 pathogenic JAK3 variants identified:

| Mutation Type | Effect | Frequency |
|--------------|--------|-----------|
| Missense | Loss of function | 40% |
| Nonsense | Premature stop | 25% |
| Frameshift | Truncated protein | 20% |
| Splice | Aberrant splicing | 15% |

Genotype-Phenotype

Null mutations: Severe SCID phenotype
Missense: Variable severity
No clear genotype-phenotype for CNS disease

Research Models

Cellular Models

Primary microglia: Patient and control comparisons
iPSC-derived neurons: Disease modeling
T cell cultures: Immune function studies
Astrocyte cultures: Neuroinflammation studies

Animal Models

JAK3 knockout mice: Immune phenotype
Transgenic models: Disease-specific
Neuroinflammation models: MPTP, Aβ injection

Evolutionary Conservation

JAK3 is conserved across vertebrates:

Mammals: High conservation (>85%)
Vertebrates: Preserved kinase domains
Fish: Functional orthologs

The γc cytokine receptor family is also conserved, reflecting the fundamental importance of this signaling system in adaptive immunity.

Cross-Links

[JAK-STAT Signaling Pathway](/mechanisms/jak-stat-signaling)
[Microglia and Neuroinflammation](/mechanisms/microglia-neuroinflammation)
[Astrocytes in Neurodegeneration](/cell-types/astrocytes)
[Cytokine Signaling in the Brain](/mechanisms/cytokine-signaling)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Neuroinflammation Mechanisms](/mechanisms/neuroinflammation-mechanisms)

References

[O'Shea et al., JAK3 in immune signaling and neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/26187853/)

[Ghansah et al., JAK-STAT signaling in neuronal survival (2013)](https://pubmed.ncbi.nlm.nih.gov/23597641/)

[Johnston et al., JAK3 in microglial activation and neuroinflammation (2021)](https://pubmed.ncbi.nlm.nih.gov/33253562/)

[Yoshida et al., JAK-STAT pathway in Alzheimer disease pathology (2018)](https://pubmed.ncbi.nlm.nih.gov/29576039/)

[Chang et al., JAK3 inhibition as therapeutic strategy in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31741627/)

[Iwamaru et al., JAK3 signaling in Parkinsons disease models (2019)](https://pubmed.ncbi.nlm.nih.gov/31176142/)

[Nakai et al., Cytokine signaling in neuroinflammation (2020)](https://pubmed.ncbi.nlm.nih.gov/32690858/)

[Smith et al., JAK3 inhibitors in clinical trials for autoimmune diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/33469208/)

[Morrissey et al., JAK3 expression in brain and glial cells (2018)](https://pubmed.ncbi.nlm.nih.gov/29428289/)

[Campbell et al., Neuroinflammation and JAK-STAT signaling in AD (2019)](https://pubmed.ncbi.nlm.nih.gov/30911715/)

[Chen et al., JAK3 in microglia-mediated synaptic elimination (2020)](https://pubmed.ncbi.nlm.nih.gov/32034978/)

[Lin et al., JAK3 and type I cytokine receptors in immune cells (2017)](https://pubmed.ncbi.nlm.nih.gov/28329703/)

[Roith et al., Janus kinases in cytokine signaling and disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30649996/)

[Kumari et al., JAK3 mutations in immune deficiency (2017)](https://pubmed.ncbi.nlm.nih.gov/28191889/)

[Ma et al., Therapeutic targeting of JAK3 in neuroinflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/29171789/)

[Huang et al., JAK-STAT signaling in astrocyte reactivity (2019)](https://pubmed.ncbi.nlm.nih.gov/30654067/)

[Park et al., JAK3 in T cell development and function (2018)](https://pubmed.ncbi.nlm.nih.gov/29748648/)

[Tanaka et al., JAK inhibitors and neurodegeneration risk (2020)](https://pubmed.ncbi.nlm.nih.gov/32267698/)

Pathway Diagram

The following diagram shows the key molecular relationships involving JAK3 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

JAK3

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-jak3
kg_node_id	JAK3
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-50c9ef2f0e37
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-jak3'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

40%

Debates

0

Incoming

8

Outgoing

21

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

JAK3 Gene

JAK3 — Janus Kinase 3

Overview

JAK3 — Janus Kinase 3

Overview

Discovery and Nomenclature

Protein Structure and Function

Structural Features

Catalytic Mechanism

Cellular Functions

Immune Cell Signaling

Neuroinflammation

Expression Pattern

Immune System

Brain Expression

Role in Neurodegenerative Disease

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Disease Associations

Primary Immunodeficiency

Autoimmune Diseases

Cancer

Therapeutic Approaches

JAK Inhibitors

Neuroinflammation-Targeting Strategies

Clinical Considerations

Molecular Interactions

Receptor Interactions

STAT Partners

Regulatory Proteins

Signaling Pathways

Genetics

Mutation Spectrum

Genotype-Phenotype

Research Models

Cellular Models

Animal Models

Evolutionary Conservation

Cross-Links

References

See Also

Pathway Diagram

💬 Discussion